Alnylam Pharmaceuticals Current Ratio 2006-2021 | ALNY

Current and historical current ratio for Alnylam Pharmaceuticals (ALNY) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Alnylam Pharmaceuticals current ratio for the three months ending June 30, 2021 was 4.91.
Alnylam Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $2.73B $0.56B 4.91
2021-03-31 $2.47B $0.50B 4.99
2020-12-31 $2.62B $0.59B 4.47
2020-09-30 $2.56B $0.48B 5.32
2020-06-30 $2.16B $0.38B 5.62
2020-03-31 $1.59B $0.34B 4.68
2019-12-31 $1.72B $0.35B 4.87
2019-09-30 $1.90B $0.35B 5.38
2019-06-30 $2.06B $0.33B 6.28
2019-03-31 $1.39B $0.15B 9.33
2018-12-31 $1.20B $0.18B 6.69
2018-09-30 $1.34B $0.12B 11.05
2018-06-30 $1.50B $0.11B 13.22
2018-03-31 $1.69B $0.12B 14.61
2017-12-31 $1.77B $0.14B 12.23
2017-09-30 $0.99B $0.10B 9.83
2017-06-30 $0.96B $0.11B 8.84
2017-03-31 $0.60B $0.10B 6.24
2016-12-31 $0.67B $0.13B 5.10
2016-09-30 $0.75B $0.08B 9.14
2016-06-30 $0.89B $0.07B 12.58
2016-03-31 $1.05B $0.07B 15.82
2015-12-31 $1.11B $0.06B 17.80
2015-09-30 $1.04B $0.06B 18.24
2015-06-30 $1.03B $0.07B 15.45
2015-03-31 $1.09B $0.08B 13.51
2014-12-31 $0.75B $0.10B 7.83
2014-09-30 $0.64B $0.06B 11.31
2014-06-30 $0.67B $0.05B 12.38
2014-03-31 $0.67B $0.08B 8.04
2013-12-31 $0.25B $0.05B 4.72
2013-09-30 $0.20B $0.06B 3.63
2013-06-30 $0.21B $0.05B 4.04
2013-03-31 $0.24B $0.05B 4.83
2012-12-31 $0.13B $0.05B 2.60
2012-09-30 $0.24B $0.06B 4.31
2012-06-30 $0.24B $0.06B 4.21
2012-03-31 $0.21B $0.07B 3.13
2011-12-31 $0.15B $0.08B 1.88
2011-09-30 $0.18B $0.09B 1.92
2011-06-30 $0.22B $0.10B 2.23
2011-03-31 $0.25B $0.10B 2.52
2010-12-31 $0.25B $0.10B 2.49
2010-09-30 $0.25B $0.10B 2.46
2010-06-30 $0.27B $0.10B 2.68
2010-03-31 $0.27B $0.10B 2.77
2009-12-31 $0.29B $0.11B 2.65
2009-09-30 $0.23B $0.10B 2.26
2009-06-30 $0.28B $0.10B 2.72
2009-03-31 $0.42B $0.10B 4.02
2008-12-31 $0.44B $0.10B 4.46
2008-09-30 $0.45B $0.10B 4.43
2008-06-30 $0.55B $0.11B 5.21
2008-03-31 $0.46B $0.09B 5.36
2007-12-31 $0.40B $0.08B 4.77
2007-09-30 $0.48B $0.09B 5.46
2007-06-30 $0.20B $0.03B 7.45
2007-03-31 $0.21B $0.02B 8.93
2006-12-31 $0.22B $0.02B 9.72
2006-09-30 $0.13B $0.02B 5.89
2006-06-30 $0.13B $0.02B 6.27
2006-03-31 $0.14B $0.02B 6.86
2005-12-31 $0.08B $0.02B 4.46
2005-09-30 $0.03B $0.01B 3.34
2005-06-30 $0.03B $0.01B 3.75
2005-03-31 $0.04B $0.01B 6.75
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $23.604B $0.493B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76